Drugs / ANK-700
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04602390 | Nov 2020 → Apr 2024 | relapsing-remitting multiple sclerosis | Anokion SA | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANK-700 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04602390 ↗ |
| Route | Intravenous | “Intravenous (IV) infusion” NCT04602390 ↗ |